To Create and Deliver the New Standard of Care in Sterile Reprocessing™

Corporate Presentation | November 20181

The statements contained in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts are forward-looking statements that involve

certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the Company‘s limited history of sales or distribution, the ability of the Company to obtain the

required regulatory clearance to market its products on a worldwide basis, the outcome of patent applications, the condition of the financial markets, the ability of the Company to obtain financing on favorable

terms and other risks and uncertainties.

Risks and uncertainties about the Company’s business are more fully discussed in the disclosure materials filed with the securities regulatory authorities in Canada, which are available on SEDAR under the issuer

profile of the Company at www.sedar.com. You are urged to read these materials.

Although management of the Company believes that the conclusions, estimates or projections reflected in such forward-looking information are reasonable and represent the Company’s conclusions, estimates

or projections at this time, such information involves unknown risks and uncertainties which may cause the Company’s actual results to differ materially from the Company’s conclusions, estimates or projections

expressed or implied by such forward-looking information. You are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, we do not undertake to update any

forward-looking statement.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of any securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.

All Dollars in USD, unless noted otherwise.

US Pats. No. 9,101,679 / 9,474,815 / 9,480,763 / 9,480,765 / 9,814,795

US Pat. Applications No. 14/820,965; 15/247,450

Canada 2,767,726 / 2,808,561

EU Pat. EP 2,601,976; EP2,609,937; EP2,482,859; EP2,601,979

Japan Pat. 5,480,975; 5,785,208; 5,785,211; 5,855,045; 6,141,950

Corresponding patents granted or pending in other countries

TSX:TOS

Important Cautions Regarding Forward Looking Statements and Other Disclosures

STERIZONE®

registered trademarks of TSO3 Inc.

© TSO3 Inc., 2018. All rights reserved for all countries. No part of this publication may be reproduced or translated in any form or by any means, without the prior written permission of TSO3 Inc.2

To Create and Deliver

The New Standard of Care

In Sterile Reprocessing™

A Sterile Device for Every Patient

VISION. PURPOSE.

3

TSX:TOS4

One Disruptive Technology – Two Large Markets

Process/

Technology

1) The American Hospital Association, US Dept. of Health and Human Services, 2) Statistica.com 2015 3) Eurostat 4) Global Low Temperature Sterilization Market: Industry Analyst & Outlook. Koncept Analytics. January 2017

5) Centers for Disease Control and Prevention 6) US Food & Drug Administration 7) Markets and Markets, June 2016 8) Becker’s GI & Endoscopy “35 Statistics About GI/Endoscopy”

OR/CSSD$6.0B+7

GI50M+

Procedures/year8

Operating Room & Central Sterile

Supply Department

U.S. ~10,000 Hospitals & Ambulatory

Surgery Centers1

Canada ~1,400 Hospitals2

Europe ~15,000 Hospitals3

Installed base of 30,000 units4

Gastrointestinal

~15M colonoscopies performed

annually5

>500,000 ERCP Procedures

(endoscopic retrograde

cholangiopancreatographies)

performed annually6

Established Base Business Emerging Opportunity

TSX:TOS

1. Insert Room Temperature Instruments Into a Warm Chamber

2. Create a Vacuum and Inject Small Amounts of Vapourized Heated Sterilant Over Time

3. Micro Condensation Forms on the Instruments

Breakthrough Technologies /// 138 Patents + 49 Patents Pending Worldwide

Dual SterilantsDual SterilantsDual SterilantsDual Sterilants

5

Condensation LayerCondensation LayerCondensation LayerCondensation Layer

TSX:TOS6

New Metric: Cost per Instrument Sterilized, not Cost per Cycle

Competition STERIZONE® VP4 Sterilizer

Saves up to 50% in Operating Costs

2 STERIZONE® VP4 Sterilizers = 3+ of

the Competition in Throughput

The Least Expensive Option In the

Market Today

* Actual customer results. Results may vary depending on the customer and use profile.

Proven Value Proposition*

TSX:TOS

Disruptive Technology for OR Support

7

The STERIZONE® VP4 Sterilizer is a dual sterilant, low-temperature sterilization system

that uses vaporized hydrogen peroxide (H2O2) and ozone.

Features Advantages Benefits

• Dual Chemistry

• Dynamic Delivery

• Large Capacity

• Lowest Cost per Instrument

Sterilized

• Improved Operating and

Service Costs

• Capital Cost Avoidance

• Expandability

• Leverage Existing Hospital

Instrument Inventory

• Reduce HAI/reputational Risk

• Simple Single Cycle

Operation

• Large Loads

• Mixed Loads

• Lower Cost

• Lower Risk

• Higher Throughput

• Ability to Process Full

Instrument Sets

• Up to 1/3 fewer

machines and cycles

TSX:TOS8

“We had 4 [competitor] Sterilizers, now

we have 2 STERIZONE® VP4 Sterilizers.”

“VP4 cost less than [competitor] in long

run”

“Service Expansion: added sleep center,

ENT scopes, endoscopy reprocessing,

neurosurgeon…”

Proven Value Proposition – Independent of Customer Size

“STERIZONE® VP4 50% less cost per

instrument sterilized than

competitor”

“Decreased Number of Cycles”

STERIZONE® VP4 Sterilizer is 3 times

more efficient than competitor

1-200 Beds 600+ Beds201-600 Beds

* Based on actual 2017 customer surveys as compared to competitive low temperature hydrogen peroxide sterilizers. Results will vary depending on the customer and use profile.

Fewer Cycles Fewer Sterilizers Better Efficiency

TSX:TOS99

Capital Equipment Sales

1-4 units per facility

Higher-Margin

Proprietary Consumables

* Assuming two units installed, 10 year product life. Based on Company Estimates. For illustrative purposes only. This illustration is based on assumptions and uncertainties as well as on management’s estimate of future events. Actual

results may differ significantly from the above illustration due to promotions, customer usage patterns, outsourcing and other material variables. Not all customers enter into service contracts. The Company has limited sales and

distribution history and there is no guarantee that our sales specialists will achieve the results illustrated herein. Refer to additional risk factors contained in TSO3‘s disclosure materials filed with the securities regulatory authorities.

Service Contracts

~10% of Capital Price/year

Potential Revenue Per US Customer*

(Assuming 2 units, 10 Yr Product Life)

$200k-$300k

$20k-$30k/Sterilizer/Year

$12k-15k/Sterilizer/yr

Approx.

$0.9m-$1.2m

Revenue

Opportunity per

Customer*

Value of a Customer

“Razor”

“Razorblades”

TSX:TOS10

Commercialization Approach - CSSD

SUPPORT WITH DIRECT

SALES, CLINICAL AND

TECHNICAL PERSONNEL

LEVERAGE EARLY

ADOPTERS

• 59 sterilizers installed in

US & Canada

• <200 beds to >1,000

beds+

INCREASE MARKET

AWARENESS

• >5,000 targeted customers

• Value Proposition Selling

ESTABLISH STRONG

CUSTOMER

TARGETING METRICS

• High Use Facilities

• Heavy Orthopedic and

Robotic Surgical Centers

• Heavy Industry and

Society Presence

• >200 opportunities

As of August 8, 2018

• Trained in-house personnel

• >30 unit installation

backlog

TSX:TOS11

Sales and Marketing Activities

• Sell Direct to End Users

• Consultative Sales Approach

• Sell With Partners/Agents

• System Wide Sales

• Strategic Pricing – Lower Capital ASPs in

exchange for speed

• New Approaches

• Cost of Ownership Tools

• Digital Ads

• Trade Shows

TSX:TOS12

Commercial Activity: As of November 6, 2018

8 Sales Reps in 8 Territories – going to 11

59 Units Installed in US and Canada

90 Units Installed or Committed in NA

200 unit goal for 2019

>200 opportunities

quoted

~5,000 accounts

targets in N. America

+10 Units Committed in October 2018 Alone

TSX:TOS13

Endoscopy Sterilization – A Greenfield Opportunity

Process/

Technology

OR/CSSD$6.0B+7

GI50M+

Procedures/year8

Operating Room & Central Sterile

Supply DepartmentGastrointestinal

~15M colonoscopies performed

annually5

>500,000 ERCP Procedures

(endoscopic retrograde

cholangiopancreatographies)

performed annually6

Established Base Business Emerging Opportunity

1) The American Hospital Association, US Dept. of Health and Human Services, 2) Statistica.com 2015 3) Eurostat 4) Global Low Temperature Sterilization Market: Industry Analyst & Outlook. Koncept Analytics. January 2017

5) Centers for Disease Control and Prevention 6) US Food & Drug Administration 7) Markets and Markets, June 2016 8) Becker’s GI & Endoscopy “35 Statistics About GI/Endoscopy”

U.S. ~10,000 Hospitals & Ambulatory

Surgery Centers1

Canada ~1,400 Hospitals2

Europe ~15,000 Hospitals3

Installed base of 30,000 units4

TSX:TOS

Technology

Advancement

Patient and Medical

Facility Demand

Regulatory

Change

• Patient Safety

• Litigation

• Cost Reduction

• STERIZONE® VP4 Sterilizer

• FDA Regulation Advancement

• Industry Dialogue and Guidelines

How Shifts Happen

= Market

Change

Market

Change

14

TSX:TOS

Old

Modernizing GI Endoscope Reprocessing

15

“Despite reprocessing in accordance with US guidelines, viable

microbes and biologic debris persisted in clinically used [GI]

endoscopes, suggesting current reprocessing guidelines are not

sufficient to ensure successful decontamination.

“Residual contamination was detected on multiple components after

reprocessing colonoscopes and EGDs in accordance with

guidelines…viable microbes were recovered from patient-ready

endoscopes (i.e., 64% post-HLD, 9% post-storage).”

- American Journal of Infection Control (with Mayo Clinic), 2015

“Strong Evidence for Sterilization of Endoscopes

Presented at Stakeholder Meeting”

- AAMI, September 2017

Decades old processes with only incremental improvement

“In an ominous sign for patient safety, 71 percent of reusable medical

scopes deemed ready for use on patients tested positive for bacteria

at three major U.S. hospitals, according to a new study.

- American Journal of Infection Control, 2018

TSX:TOS

TSO3 Obtains Expanded Endoscope Clearances

16

Source: Olympus America Inc.

May 9, 2018 - TSO3 received FDA 510(k) clearance for the terminal sterilization of

multi-channeled flexible endoscopes using the Company’s STERIZONE® VP4

Sterilizer

• Hospitals can terminally sterilize gastrointestinal

endoscopes within the cleared intended use

• Colonoscopes, duodenoscopes and gastroscopes

STERIZONE® VP4 Sterilizer is the only terminal sterilization method that is FDA cleared to sterilize

multi-channeled flexible endoscopes (with a maximum of four channels) with inside diameters of

1.2mm or more and lengths of 1955mm or less, or 1.45mm or more and lengths of 3500mm or less.

TSX:TOS17

Recent Customer Activity

Altru Health System Improves Patient Care with Expanded Use of Cutting-Edge Sterilization

Technology

June 15, 2018 - “Being the inaugural facility to offer terminal sterilization of endoscopes using the TSO3 technology,

provides our patients with a level of safety above current best-practice standards in the industry,” says Stacie Avdem,

Director of Surgical and Procedural Services at Altru Health System.

“Altru has achieved industry leading practices with

centralization, cleaning verification, and borescope inspection in

endoscope reprocessing. The ability to sterilize endoscopes,

specifically duodenoscopes, is paramount to achieving our

mission of delivering world-class care to the residents of our

region. It shows our ongoing investment in and commitment to

patient safety,” says Jenni Gibbs, Manager of Central Sterile

Department at Altru Health System.

Next Generation TechnologyNext Generation TechnologyNext Generation TechnologyNext Generation Technology

Extensive Patent Portfolio Extensive Patent Portfolio Extensive Patent Portfolio Extensive Patent Portfolio

Razor/Razor/Razor/Razor/RazorbladeRazorbladeRazorbladeRazorblade Business ModelBusiness ModelBusiness ModelBusiness Model

FirstFirstFirstFirst----totototo----Market FDAMarket FDAMarket FDAMarket FDA----cleared Device for Terminal Sterilization of cleared Device for Terminal Sterilization of cleared Device for Terminal Sterilization of cleared Device for Terminal Sterilization of

Colonoscopes, Duodenoscopes and GastroscopesColonoscopes, Duodenoscopes and GastroscopesColonoscopes, Duodenoscopes and GastroscopesColonoscopes, Duodenoscopes and GastroscopesSUMMARYSUMMARYSUMMARYSUMMARY

Direct Commercialization StrategyDirect Commercialization StrategyDirect Commercialization StrategyDirect Commercialization Strategy

FinanciallyFinanciallyFinanciallyFinancially SoundSoundSoundSound

TSX:TOS18

TSX:TOS

Key Stats (TSX: TOS) /// All Dollars in USD, Unless Noted Otherwise

(mrq) = most recent quarter at September 30, 2018

• 2018 financial data is of September 30, 2018. On August 1, 2018, the Company closed $20 million in debt financing. See www.tso3.com 19

Stock Price (11/23/18) CAD$0.48

52 Week High-Low CAD$2.83-$0.38

Shares Outstanding (mrq) (no warrants) 93.2M

Average Daily Volume (90 day) 122,900

Market Capitalization CAD$44.8M

Institutional Holdings ~15%

Total Revenue (mrq) $0.8M

Cash and ST Investments (9/30/18) $16.1M

20